Global Information
회사소개 | 문의

췌장암 : 파이프라인 리뷰

Pancreatic Cancer - Pipeline Review, H2 2018

리서치사 Global Markets Direct
발행일 2018년 12월 상품 코드 200987
페이지 정보 영문 2787 Pages
가격
US $ 2,500 ₩ 2,847,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 5,694,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,500 ₩ 8,541,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


췌장암 : 파이프라인 리뷰 Pancreatic Cancer - Pipeline Review, H2 2018
발행일 : 2018년 12월 페이지 정보 : 영문 2787 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

췌장암이란 췌장 조직에 악성세포(암세포)가 발생하는 질환으로, 외분비계 암이라고도 불리고 있습니다. 주요 징후 및 증상으로 상복부통과 등으로의 확산, 황달, 식욕 부진, 체중 감소, 혈병 등이 있습니다. 주요 질병 소질에는 연령과 성별, 흡연, 당뇨병, 가족력 등이 있습니다. 주요 치료법으로는 외과 수술, 화학요법, 방사선 치료 등이 있습니다.

세계 각국에서의 췌장암(Pancreatic Cancer) 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 파이프라인 제품의 최신 동향, 임상시험 각 단계의 제품 목록, 주요 기업 개요, 주요 약제 개요, 최신 업계 동향 등의 정보를 전해드립니다.

서론

췌장암 개요

치료제 개발

췌장암 : 기업에서 개발중인 치료제

췌장암 : 대학/기관에서 연구중인 치료제

췌장암 : 파이프라인 제품 개요

췌장암 : 기업에서 개발중인 제품

췌장암 : 대학/기관에서 연구중인 제품

췌장암 치료제 개발에 참여하고 있는 기업

췌장암 : 치료제 평가

약제 개요

췌장암 : 휴지중인 프로젝트

췌장암 : 개발이 중지된 제품

췌장암 : 제품 개발 마일스톤

부록

KSM 16.08.03

List of Tables

  • Number of Products under Development for Pancreatic Cancer, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Stage and Target, H2 2018
  • Number of Products by Stage and Mechanism of Action, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Pancreatic Cancer - Pipeline by 3-V Biosciences Inc, H2 2018
  • Pancreatic Cancer - Pipeline by 4P-Pharma SAS, H2 2018
  • Pancreatic Cancer - Pipeline by 4SC AG, H2 2018
  • Pancreatic Cancer - Pipeline by AB Science SA, H2 2018
  • Pancreatic Cancer - Pipeline by AbbVie Inc, H2 2018
  • Pancreatic Cancer - Pipeline by AbGenomics International Inc, H2 2018
  • Pancreatic Cancer - Pipeline by Ability Pharmaceuticals SL, H2 2018
  • Pancreatic Cancer - Pipeline by Aclaris Therapeutics Inc, H2 2018
  • Pancreatic Cancer - Pipeline by Actuate Therapeutics Inc, H2 2018
  • Pancreatic Cancer - Pipeline by Adamed Sp z oo, H2 2018
  • Pancreatic Cancer - Pipeline by ADC Therapeutics SA, H2 2018
  • Pancreatic Cancer - Pipeline by Aduro BioTech Inc, H2 2018
  • Pancreatic Cancer - Pipeline by Advanced BioDesign, H2 2018
  • Pancreatic Cancer - Pipeline by Advantagene Inc, H2 2018
  • Pancreatic Cancer - Pipeline by Advanz Pharmaceutical Corp , H2 2018
  • Pancreatic Cancer - Pipeline by Advenchen Laboratories LLC, H2 2018
  • Pancreatic Cancer - Pipeline by Agency for Science, Technology and Research, H2 2018
  • Pancreatic Cancer - Pipeline by AGV Discovery SAS, H2 2018
  • Pancreatic Cancer - Pipeline by AIMM Therapeutics BV, H2 2018
  • Pancreatic Cancer - Pipeline by Alissa Pharma, H2 2018
  • Pancreatic Cancer - Pipeline by Alligator Bioscience AB, H2 2018
  • Pancreatic Cancer - Pipeline by Allinky Biopharma SL, H2 2018
  • Pancreatic Cancer - Pipeline by Almac Discovery Ltd, H2 2018
  • Pancreatic Cancer - Pipeline by Altor BioScience Corp, H2 2018
  • Pancreatic Cancer - Pipeline by ALX Oncology Inc, H2 2018
  • Pancreatic Cancer - Pipeline by Ambrx Inc, H2 2018
  • Pancreatic Cancer - Pipeline by amcure GmbH, H2 2018
  • Pancreatic Cancer - Pipeline by Amgen Inc, H2 2018
  • Pancreatic Cancer - Pipeline by Amplia Therapeutics Ltd, H2 2018
  • Pancreatic Cancer - Pipeline by Anavex Life Sciences Corp, H2 2018
  • Pancreatic Cancer - Pipeline by Andarix Pharmaceuticals Inc, H2 2018
  • Pancreatic Cancer - Pipeline by ANP Technologies Inc, H2 2018
  • Pancreatic Cancer - Pipeline by AntiCancer Inc, H2 2018
  • Pancreatic Cancer - Pipeline by APEIRON Biologics AG, H2 2018
  • Pancreatic Cancer - Pipeline by Apexigen Inc, H2 2018
  • Pancreatic Cancer - Pipeline by Aphios Corp, H2 2018
  • Pancreatic Cancer - Pipeline by Aposense Ltd, H2 2018
  • Pancreatic Cancer - Pipeline by Aravive Inc, H2 2018
  • Pancreatic Cancer - Pipeline by ArQule Inc, H2 2018
  • Pancreatic Cancer - Pipeline by Array BioPharma Inc, H2 2018

List of Figures

  • Number of Products under Development for Pancreatic Cancer, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Top 10 Targets, H2 2018
  • Number of Products by Stage and Top 10 Targets, H2 2018
  • Number of Products by Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Top 10 Routes of Administration, H2 2018
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2018
  • Number of Products by Top 10 Molecule Types, H2 2018
  • Number of Products by Stage and Top 10 Molecule Types, H2 2018

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatic Cancer - Pipeline Review, H2 2018, provides an overview of the Pancreatic Cancer (Oncology) pipeline landscape.

Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. This is also called exocrine cancer. Signs and symptoms include upper abdominal pain that may radiate to back, yellowing of skin and the whites of eyes (jaundice), loss of appetite, weight loss, depression and blood clots. Predisposing factors include age, gender, smoking, diabetes and family history. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pancreatic Cancer - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Pancreatic Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pancreatic Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pancreatic Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 20, 165, 153, 3, 8, 296, 39 and 9 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages comprises 20, 10, 2, 1, 56 and 8 molecules, respectively.

Pancreatic Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pancreatic Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Pancreatic Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pancreatic Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pancreatic Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pancreatic Cancer (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pancreatic Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pancreatic Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Pancreatic Cancer - Overview
  • Pancreatic Cancer - Therapeutics Development
  • Pancreatic Cancer - Therapeutics Assessment
  • Pancreatic Cancer - Companies Involved in Therapeutics Development
  • Pancreatic Cancer - Drug Profiles
  • Pancreatic Cancer - Dormant Projects
  • Pancreatic Cancer - Discontinued Products
  • Pancreatic Cancer - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q
 
BCC Research